| (Values in U.S. Thousands) | Dec, 2016 | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -32,500 | -15,610 | -29,860 | 86,890 | 4,570 |
| Net Income Growth | -108.20% | +47.72% | -134.37% | +1,801.31% | unch |
Neuroderm Ltd Ord Sh (NDRM)
38.85 -0.05 (-0.13%) 10/17/17 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime - - (-) -
for Tue, Oct 17th, 2017
Neuroderm Ltd. is a clinical-stage pharmaceutical company. It is developing next-generation treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson's disease (PD). Its product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. NeuroDerm Ltd. is headquartered in Rehovot, Israel.
Fiscal Year End Date: 12/31